The incidence of severe hypoglycemia in type 1 diabetes has not decreased over the past decades. New treatment modalities minimizing the risk of hypoglycemic episodes and attenuating hypoglycemic cognitive dysfunction are needed. We studied if treatment with the neuroprotective hormone erythropoietin (EPO) enhances cognitive function during hypoglycemia.
P L O S One, 2013, Vol 8, Issue 4, p. 1-8
Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't